Literature DB >> 4142650

Biological effects of 5-azacytidine in eukaryotes.

A Cihák.   

Abstract

5-Azacytidine (NSC-102 816) was prepared synthetically and independently isolated from the culture filtrate of Streptoverticillium ladakanus. It is an s-triazine analogue of cytidine possessing a broad spectrum of biological effects. In mammalian tissueit is phosphorylated to 5-azacytidine 5-phosphates and incorporated into different species of RNAs and into DNA. 5-Azacytidine 5-monophosphate inhibits orotidine 5-phosphate decarboxylase blocking thus the de novo pyrimidine synthesis. Following the administration of 5-azacytidine a rapid breakdown of liver polyribosomes has been observed; furthermore, in different systems a profound inhibitory effect of the drug on the maturation of ribosomal RNA has been found. 5-Azacytidine interferes with different induced liver enzymes; in some cases their activity is elevated since the rate of enzyme degradation is decreased. The cytostatic effect of the drug is directed primarily against lymphatic leukemia although some recent reports indicate its action also against human solid tumours. Chemotherapy of leukemic mice by 5-azacytidine results simultaneously in the depressed synthesis of liver and spleen polyamines. 5-Azacytidine exhibits furthermutagenic, abortive, immunosuppressive, antimitotic, radioprotective and virostatic effects. The drug also affects DNA and protein synthesis in embryonic tissues, cells intissue culture, regenerating livers, in bacteria and phages. The changes associated with the emergence of resistance towards 5-azacytidine are associated with the decreased activity of uridine kinase in mouse leukemia cells. On the contrary, in adult rate livers5-azacytidine administration leads to the increased activity of this enzyme. Differentauthors have used 5-azacytidine as a tool for the study of biochemical mechanisms connected with a cell proliferation and division.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4142650     DOI: 10.1159/000224981

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  53 in total

1.  A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors.

Authors:  Fang Zhang; Amy R Frost; Mike P Blundell; Olivia Bales; Michael N Antoniou; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-06-29       Impact factor: 11.454

2.  The use of 5-azacytidine to increase cleavage of methylation sensitive rare cutting restriction enzymes sites in amplified DNA.

Authors:  E Heard; M Fried
Journal:  Nucleic Acids Res       Date:  1990-10-25       Impact factor: 16.971

3.  The epigenetic drug 5-azacytidine interferes with cholesterol and lipid metabolism.

Authors:  Steve Poirier; Samaneh Samami; Maya Mamarbachi; Annie Demers; Ta Yuan Chang; Dennis E Vance; Grant M Hatch; Gaétan Mayer
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

4.  γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?

Authors:  Jaydeep Bhat; Dieter Kabelitz
Journal:  Oncoimmunology       Date:  2015-04-28       Impact factor: 8.110

5.  Hypomethylating drugs efficiently decrease cytosine methylation in telomeric DNA and activate telomerase without affecting telomere lengths in tobacco cells.

Authors:  Eva Majerová; Miloslava Fojtová; Iva Mozgová; Miroslava Bittová; Jiří Fajkus
Journal:  Plant Mol Biol       Date:  2011-08-25       Impact factor: 4.076

6.  DNA demethylation induced by 5-azacytidine does not affect fragile X expression.

Authors:  T W Glover; J Coyle-Morris; L Pearce-Birge; C Berger; R M Gemmill
Journal:  Am J Hum Genet       Date:  1986-03       Impact factor: 11.025

7.  Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.

Authors:  Gautam Borthakur; Xuelin Huang; Hagop Kantarjian; Stefan Faderl; Farhad Ravandi; Alessandra Ferrajoli; Ritva Torma; Gail Morris; Donald Berry; Jean-Pierre Issa
Journal:  Leuk Lymphoma       Date:  2010-01

8.  Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice.

Authors:  J Quddus; K J Johnson; J Gavalchin; E P Amento; C E Chrisp; R L Yung; B C Richardson
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

9.  A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.

Authors:  Paul W Hollenbach; Aaron N Nguyen; Helen Brady; Michelle Williams; Yuhong Ning; Normand Richard; Leslie Krushel; Sharon L Aukerman; Carla Heise; Kyle J MacBeth
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

10.  DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine.

Authors:  Jarah A Meador; Yanrong Su; Jean-Luc Ravanat; Adayabalam S Balajee
Journal:  Carcinogenesis       Date:  2009-11-23       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.